Cell News and Research

RSS

Hybrid concierge practice models stress prevention and wellness

The nation's leading provider of hybrid concierge medicine, Concierge Choice Physicians, sees historic opportunities for patients and physicians under the recently enacted healthcare law. Hybrid concierge practice models emphasize prevention and wellness and give physicians a way to offer a concierge option while continuing to care for all of their patients.

1 Apr 2010

Soligenix's revenues for 2009 increase by 22%

Soligenix, Inc., a late-stage biopharmaceutical company, today announced its financial results for 2009.

1 Apr 2010

BeaconEquity.com announces investment report featuring OXiGENE

BeaconEquity.com announces an investment report featuring OXiGENE Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

1 Apr 2010

Ensuring medication compliance in clinical trials: Pill capsules with microchips to signal ingestion

Seeking a way to confirm that patients have taken their medication, University of Florida engineering researchers have added a tiny microchip and digestible antenna to a standard pill capsule. The prototype is intended to pave the way for mass-produced pills that, when ingested, automatically alert doctors, loved ones or scientists working with patients in clinical drug trials.

1 Apr 2010

Mtb fine-tunes behaviour to escape detection and causes TB

Mycobacterium tuberculosis (Mtb) possesses extraordinary survival ability by masking itself from the host immune system and persisting for decades inside the host. Speaking at the Society for General Microbiology's spring meeting in Edinburgh today, Dr Kristine Arnvig provides further insight into how the bacterium causes tuberculosis (TB) by fine-tuning its behaviour in response to its surroundings to escape detection.

1 Apr 2010

Scientists use non-viral, synthetic nanoparticle carrier to restores vision

Take a look at this: Scientists from Buffalo, Cleveland, and Oklahoma City made a huge step toward making the blind see, and they did it by using a form of gene therapy that does not involve the use of modified viruses.

1 Apr 2010

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

Peregrine Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing innovative monoclonal antibodies for the treatment of cancer and viral infections, today announced four studies of bavituximab and its other PS-targeting antibodies have been accepted for presentation at the 101st Annual Meeting of the American Association for Cancer Research to be held April 17-21, 2010 in Washington, D.C.

1 Apr 2010

Combating immune suppressive cells in liver may prevent the spread of cancer: Study

Scientists have uncovered what could be a very important clue in answering one of the most perplexing questions about cancer: why does it spread to the liver more than any other organ? In a new research report published in the April 2010 issue of Journal of Leukocyte Biology, scientists from New York University describe experimental results suggesting that the immune system may be the reason.

1 Apr 2010

Masimo PVI predicts hemodynamic effects of PEEP in mechanically ventilated patients

Masimo, the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low Perfusion pulse oximetry, announced today that a new clinical study published in the March 2010 issue of Anesthesia & Analgesia, shows Masimo PVI successfully predicts the hemodynamic effects of Positive End-Expiratory Pressure in mechanically ventilated patients after cardiac surgery.

1 Apr 2010

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

Symphogen A/S today announced that it has initiated a Phase 1/2 human clinical trial in the US to evaluate the safety, tolerability and efficacy of its drug candidate Sym004 for the treatment of advanced solid tumors. Sym004 is composed of two anti-epidermal growth factor receptor monoclonal antibodies targeting different nonoverlapping EGFR epitopes.

1 Apr 2010

Role of membrane cholesterol in late keratinocyte differentiation analyzed

In a recent study initiated by Beiersdorf AG, Florian Spörl and colleagues evaluated the use of Roche Applied Science's xCELLigence System as a viable system to monitor not only cholesterol extraction and repletion but also cholesterol reorganization in human keratinocytes in real time. The xCELLigence System offers a novel approach to non-invasive long-term observation of membrane cholesterol dynamics in primary human keratinocytes.

1 Apr 2010

JEBDP to commemorate 10th anniversary by distributing special issue on restorative dentistry

Elsevier, a world leader in health care and medical publishing and online solutions, today announced that its Journal of Evidence-Based Dental Practice will celebrate its 10th anniversary by distributing a special March 2010 issue on restorative dentistry to faculty members, senior dental students and all dental residents in the U.S.

1 Apr 2010

Canadian Blood Services renews partnership with DDB Canada and OMD Canada

Canadian Blood Services has renewed its partnership with DDB Canada and OMD Canada; signing a new, three-year contract for strategic advertising and media management services. Both DDB and OMD will continue to help recruit and retain the next generation of blood donors in Canada, in addition to helping expand and diversify the OneMatch Stem Cell and Marrow Network.

1 Apr 2010

Cell study may yield new treatment strategies for debilitating diseases

A Los Alamos National Laboratory toxicologist and a multidisciplinary team of researchers have documented potential cellular damage from "fullerenes"-soccer-ball-shaped, cage-like molecules composed of 60 carbon atoms. The team also noted that this particular type of damage might hold hope for treatment of Parkinson's disease, Alzheimer's disease, or even cancer.

1 Apr 2010

New medicines to fight diseases of particular concern to African Americans

A recent article in The Triangle Tribune pointed to good news for members of the black community, highlighting new medicines in development to fight diseases of particular concern to African Americans.

1 Apr 2010

EMBL scientists identify genes involved in human cell division

Name a human gene, and you'll find a movie online showing you what happens to cells when it is switched off. This is the resource that researchers at the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany, and their collaborators in the Mitocheck consortium are making freely available, as the result of a study in which they have identified the genes involved in mitosis - the most common form of cell division - in humans.

1 Apr 2010

Cord Blood America signs License and Cooperation Agreement with AXM Pharma in China

Cord Blood America, Inc., the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, announced today that it has signed a License and Cooperation Agreement for the processing and storage of umbilical cord blood in China with AXM Pharma, Inc.

1 Apr 2010

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

Genta Incorporated today announced that the Company has initiated a confirmatory Phase 2b trial of tesetaxel in patients with advanced gastric cancer. Tesetaxel is the Company's newest clinical-stage small molecule. As a late Phase 2 oncology product, tesetaxel is the leading oral taxane currently in clinical development.

31 Mar 2010

Japanese Patent Office grants Alnylam Pharmaceuticals' claims in second patent application for Tuschl II

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the Japanese Patent Office has granted claims in a second patent application (JP Application Number 2006-317758) for the Tuschl II patent series, entitled "RNA Interference Mediating Small RNA Molecules." In May 2008, the Japanese Patent Office granted a related set of claims in the Tuschl II patent series (JP 4 095 895).

31 Mar 2010

Rosetta Genomics reports revenues of $150,000 for full-year 2009

Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, today reported that on March 26, 2010 the Company filed its Form 20-F with the U.S. Securities and Exchange Committee, which contains financial results for the three and 12 months ended December 31, 2009.

31 Mar 2010

Cell News and Research

Hybrid concierge practice models stress prevention and wellness

Soligenix's revenues for 2009 increase by 22%

BeaconEquity.com announces investment report featuring OXiGENE

Ensuring medication compliance in clinical trials: Pill capsules with microchips to signal ingestion

Mtb fine-tunes behaviour to escape detection and causes TB

Scientists use non-viral, synthetic nanoparticle carrier to restores vision

Four studies of bavituximab and PS-targeting antibodies to be presented at AACR 2010

Combating immune suppressive cells in liver may prevent the spread of cancer: Study

Masimo PVI predicts hemodynamic effects of PEEP in mechanically ventilated patients

Phase 1/2 human clinical trial of Symphogen's Sym004 initiated in the US

Role of membrane cholesterol in late keratinocyte differentiation analyzed

JEBDP to commemorate 10th anniversary by distributing special issue on restorative dentistry

Canadian Blood Services renews partnership with DDB Canada and OMD Canada

Cell study may yield new treatment strategies for debilitating diseases

New medicines to fight diseases of particular concern to African Americans

EMBL scientists identify genes involved in human cell division

Cord Blood America signs License and Cooperation Agreement with AXM Pharma in China

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

Japanese Patent Office grants Alnylam Pharmaceuticals' claims in second patent application for Tuschl II

Rosetta Genomics reports revenues of $150,000 for full-year 2009

What are the challenges of cell line development? eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo